Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navlimetostat + Pumitamig in MTAP-Deficient Advanced NSCLC
NCT07579221Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2026
- Primary completion
- Aug 2029
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of navlimetostat, pumitamig in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2026; status: recruiting.
02
Drugs
navlimetostatpumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07579221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07579221.